Other Information
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the quarter ended March 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended March 31, 2024.
Exhibit Number
−Removed: Amendment to Convertible Promissory Note, dated June 30, 2023, by and between NRx Pharmaceuticals, Inc.
−Removed: and Streetervillle Capital LLC.
+Added: Incorporation by Reference
+Added: Underwriting Agreement, dated April 18, 2024, by and between NRx Pharmaceuticals, Inc.
+Added: and EF Hutton LLC,
+Added: Exhibit 1.1 to the Current Report on Form 8-K, filed on April 19, 2024
+Added: Exhibit Number
+Added: Incorporation by Reference
+Added: Form of Underwriter’s Warrant between NRx Pharmaceuticals, Inc.
+Added: issued April 19, 2024.
+Added: Exhibit 4.1 to the Current Report on Form 8-K, filed on April 19, 2024
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
2 unchanged sentences
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
+Added: Notice by Streeterville Capital, LLC.
+Added: Exhibit 99.1 to the Current Report on Form 8-K, filed on April 30, 2024
Interactive data files pursuant to Rule 405 of Regulation S-T formatted in Inline XBRL:
−Removed: (i) Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022;
−Removed: (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022 ;
−Removed: (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the nine months ended September 30, 2023 and 2022;
−Removed: (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022;
+Added: (i) Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023;
+Added: (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023 ;
+Added: (iii) Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) for the three months ended March 31, 2024 and 2023;
+Added: (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023;
and (v) Notes to Unaudited Financial Statements.
6 unchanged sentences
NRX PHARMACEUTICALS, INC.
−Removed: November 14, 2023
/s/ Richard Narido
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.